N@N

Curis to Release Second Quarter 2010 Financial Results and Hold Conference Call on August 3, 2010

_{//health-fitness.news-articles.net/content/2010/ .. s-and-hold-conference-call-on-august-3-2010.html}
^{Published in Health and Fitness on Tuesday, July 27th 2010 at 5:13 GMT by Market Wire}  

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its second quarter 2010 financial results on Tuesday, August 3, 2010 before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss: (i) its Hedgehog pathway inhibitor program under collaboration with Genentech, (ii) CUDC-101, Debio 0932 and its other targeted cancer programs, (iii) its financial results as of and for the three- and six-month periods ended June 30, 2010, and (iv) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.

To access the live conference call, please call (866) 543-6408 from the United States or Canada or (617) 213-8899 from other locations, shortly before 9:00 A.M. EDT. The conference ID number is 51690637. The conference call can also be accessed on the Curis website at [ www.curis.com ] in the Investors section. Replay will be available approximately two hours after the completion of the call and through 12:00 P.M. EDT, Tuesday, August 10, 2010. To access the replay, please call (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference the conference ID number 35133071.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at [ www.curis.com ].